by Raynovich Rod | Jun 3, 2013 | BIOgraph, Biopharmaceuticals
Sell On ASCO News Due to High Expectations? Large Cap Drugs Outperform Biotechs As we move through the first day of ASCO and much anticipated clinical developments the market should not be surprised that large cap drug stocks are also major biotech stocks: Bristol...
by Raynovich Rod | Jun 3, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Biopharmaceuticals
Raise More Cash- No Change in Rayno Biopharma Portfolio Last month we raised the yellow flag on the biotech sector because of a choppy tape, new highs with weakness in MO (Momentum) plays and the anticipation of ASCO news that could trigger a “sell on the...
by Raynovich Rod | May 29, 2013 | BIOgraph, Biopharmaceuticals
Biopharmaceutical Stocks Sell-Off with Large Cap Drug Stocks High Flyers du jour-AEGR,INFI 10 Year Treasury Hits 2.13 Yield Caution-no new buys and all portfolio positions on hold Large cap drug stocks were the surprising loser today along with the healthcare sector...
by Raynovich Rod | May 22, 2013 | BIOgraph, Biopharmaceuticals
Biotechs Bounce Back After Deep Dive Unless you were trading at the open today and covered your shorts you could have been whipsawed in a volatile market that had NASDAQ down to the 3425 level. Many biotech stocks recovered today so no technical damage. The IBB was...
by Raynovich Rod | May 21, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Biopharmaceutical Stocks Rally- Many Rayno Picks up 2%+ If the past four days was the long awaited biotechnology correction it was barely noticeable, a mere 3.7% high to low over the past week.Today the rally has resumed with major large cap holdings from funds and...
by Raynovich Rod | May 16, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Damage held to the AM-IBB Holds at $180 Two Volatile Stocks Green stocks in our coverage universe: ACHN, BIIB, CBST. Volume on all biotech stocks was above average, so review technicals as this could be a correction in the sector. We have not changed any of our...
by Raynovich Rod | May 14, 2013 | BIOgraph, Biopharmaceuticals
BioBubble with No Trouble? Another green screen today with the usual suspects running in Rayno Biopharmaceuticals helped by the Bank of America Health Care Conference. Alexion (ALXN) up 2.86%, Biogen Idec (BIIB) up 3.19%, Gilead (GILD) up 3.27%, Pharmacyclics (PCYC)...
by Raynovich Rod | May 8, 2013 | BIOgraph, Biopharmaceuticals
ASCO Meeting Coming Up May 31 With the ASCO Meeting coming up at the end of the month, we are pleased to provide oncology pipeline data from Linda Pullan. There was a lot of interest on this WEB site when we provided data in June 2010. The link is Pullan’s...
by Raynovich Rod | May 6, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Rayno Biopharma Portfolio We are still cautious on adding new biotech positions except stocks that were mentioned last month (see Alkermes ALKS, Array ARRY and Achillion ACHN). Many biotech MO stocks are well off their highs. All positions remain as HOLDS unless you...
by Raynovich Rod | May 1, 2013 | BIOgraph, Biopharmaceuticals
Regeneron (REGN) Up 30 Points On Allergan Delays For Vision Loss Drug As news came out from an Allergan (AGN $98.5) off 12%, conference call that their vision loss drug would be delayed, Regeneron shares soared 14%. Regeneron now has a market cap of $24B with a PE of...
